查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2161669

脂質奈米顆粒市場：按產品、類型、分子、應用、服務類型、最終用戶和地區分類－全球預測至2031年

Lipid Nanoparticles Market by Product (Ionizable lipids, Phospholipids, Neutral Lipids), Type (SLNs, NLCs), Molecule (siRNA, mRNA), Application, Service Type (Formulation Development, Manufacturing), End User, Region - Global Forecast to 2031
出版日期: | 出版商: MarketsandMarkets | 英文 336 Pages | 訂單完成後即時交付

價格

全球 LNP 原物料市場預計將從 2026 年的 2.988 億美元成長到 2031 年的 3.95 億美元，預計 2026 年至 2031 年的複合年成長率將達到 5.7%。

全球 LNP 服務市場預計將從 2026 年的 1.61 億美元成長到 2031 年的 3.092 億美元，同期複合年成長率為 13.9%。

調查範圍
調查期 2026-2031
基準年 2025
預測期 2026-2031
計算單位 金額（百萬美元）
部分 產品、LNP產品類型、分子、應用、原料、最終用戶、服務、服務的最終用戶以及地區
目標區域 北美洲、歐洲、亞太地區、拉丁美洲、中東和非洲

市場成長主要受mRNA疫苗和療法、siRNA藥物、基因編輯療法以及其他需要高效胞內遞送的核酸類產品的研發和商業化進程的推動。離子化脂質、聚乙二醇化脂質、磷脂質、製劑技術以及可擴展的脂質奈米顆粒（LNP）生產技術的持續創新也進一步促進了其應用。然而，藥用級脂質的高成本和嚴格的品質要求、製劑穩定性方面的限制、規模化生產和批間重現性方面的挑戰，以及複雜的監管和CMC要求，預計將限制市場的進一步成長。

脂質奈米顆粒市場-IMG1

“到 2025 年，從單一產品來看，離子化脂質細分市場將在脂質奈米顆粒市場中佔據最大佔有率。”

從產品角度來看，脂質奈米顆粒（LNP）原料市場可細分為離子化脂質、聚乙二醇化脂質、中性脂質、核內體、試劑盒和試劑以及其他製劑材料。預計到2025年，離子化脂質將佔據LNP原料市場最大的佔有率，這主要歸功於其在核酸包封、內體逃脫、細胞內遞送效率以及LNP整體性能方面發揮的核心作用。離子化脂質廣泛應用於mRNA、siRNA和其他RNA製劑中，因為它們在生理pH值下保持近中性，而在酸性環境下則發生質子化，促進載體釋放到細胞質中。獨特的離子化脂質化學、可生物分解的脂質結構以及組織選擇性遞送系統的持續發展，不斷支撐著製藥公司、生物技術公司和合約研發生產機構（CDMO）的強勁需求。

“從 2026 年到 2031 年，按分子類型來看，mRNA 細分市場預計將成為 LNP 市場中成長最快的細分市場。”

依分子類型分類，全球脂質奈米顆粒（LNP）市場可分為siRNA、mRNA和其他分子。在預測期內，mRNA細分市場預計將呈現最高的複合年成長率（CAGR），這主要得益於預防性和治療性疫苗、癌症治療方案、蛋白質替代療法以及其他基於mRNA的藥物研發管線的擴展。 LNP是mRNA療法的關鍵遞送平台，因為它們能夠保護mRNA免受酵素分解，促進細胞內攝取，並實現高效的細胞內釋放。除了LNP驅動的mRNA產品的臨床和商業性化應用外，對下一代mRNA平台的投資增加以及其應用範圍擴展到感染疾病以外的更廣泛治療領域，預計也將加速對專用LNP原料、製劑開發和生產服務的需求。

“預計從2026年到2031年，亞太地區脂質奈米顆粒市場的複合年成長率將最高。”

脂質奈米顆粒（LNP）市場按地區分類為北美、歐洲、亞太、拉丁美洲以及中東和非洲。在預測期內，亞太地區預計將實現最高的複合年成長率（CAGR），這主要得益於生物製藥和疫苗生產能力的提升、對RNA療法和先進藥物遞送技術投資的增加，以及區域性合約研發生產機構（CDMO）的成長。中國、日本、韓國和印度等國家正在加強其在脂質合成、製劑開發、核酸療法和商業化生產方面的能力。政府對生物技術的支持力度加大、研發活動的活性化以及全球和區域性製藥企業業務的拓展，預計也將推動脂質奈米顆粒在全部區域的應用。

本報告所進行的主要訪談依下列類別分類：

  • 依受訪者統計：供給面下降70%，需求面下降30%
  • 依公司規模分類：一級公司 - 40%，二級公司 - 30%，三級公司 - 30%
  • 按職位分類：首席主管和總監 - 30%，經理 - 45%，其他 - 25%
  • 區域細分：北美 -40%，歐洲 -25%，亞太地區 -20%，拉丁美洲 -10%，中東 -5%

調查範圍

本報告詳細闡述了影響脂質奈米顆粒（LNP）市場成長的關鍵因素，包括促進因素、挑戰、機會和限制因素。報告深入分析了主要行業參與者，概述了他們的業務概況、LNP相關原料和服務組合，以及產品發布、合作、夥伴關係、協議、收購、許可活動和近期市場動態等關鍵策略。此外，報告還對主要原料供應商、製劑技術公司、合約研發生產機構（CDMO）以及LNP生態系統中的其他參與企業進行了競爭評估。

購買本報告的主要好處

本報告透過提供脂質奈米顆粒市場及其細分市場最準確的銷售預測，幫助市場領導者和新參與企業更了解市場。此外，本報告還有助於相關人員深入了解競爭格局，更有效地進行市場定位，並制定合適的市場進入和成長策略。透過本報告，相關人員可以掌握市場趨勢，並獲取整體脂質奈米顆粒原料、製劑開發和生產服務等關鍵市場促進因素、限制因素、機會和挑戰的資訊。

本報告深入分析了以下幾點：

  • 對影響脂質奈米顆粒市場成長的因素進行分析，包括關鍵促進因素（mRNA 和 RNA 治療管線的擴展、基於 LNP 的核酸遞送技術的日益普及以及離子化脂質化學和製劑技術的持續創新）、阻礙因素（藥用級脂質和製劑成分的高成本和嚴格的質量要求）、機遇（可生物分解和組織可開發和組織化合物療法中的廣泛應用）和挑戰（規模化、批次間重現性、製劑穩定性以及複雜的 CMC 和監管要求）。
  • 產品開發/創新：深入了解新開發的 LNP 原料、離子化脂質、配方技術和服務能力。
  • 市場發展：盈利市場的全面資訊－本報告分析了各個地區脂質奈米顆粒的發展趨勢。
  • 市場多元化：有關 LNP 市場的新產品和服務、未開發的地區、近期趨勢、合作夥伴關係、許可活動和投資的全面資訊。
  • 競爭分析：對主要公司的市場佔有率、成長策略和產品/服務進行詳細評估。

目錄

第1章：引言

第2章執行摘要

第3章重要考察

  • LNP原料與服務市場概覽
  • 北美：按產品類型和國家分類的LNP原料市場
  • LNP原料市場：區域成長機遇
  • LNP原料市場佔有率（依最終用戶分類，2026年與2031年比較）（%）
  • LNP 服務市場佔有率（以最終用戶分類，2026 年與 2031 年對比）（%）

第4章 市場概覽

  • 市場動態
    • 促進因素
    • 抑制因子
    • 機會
    • 任務
  • 未滿足的需求和未開發的領域
  • 相互關聯的市場與跨產業機遇
  • 一級/二級/三級主要公司的策略性舉措

第5章 產業趨勢

  • 波特五力分析
    • 競爭公司之間的競爭
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
  • 宏觀經濟展望
    • GDP趨勢與預測
    • GDP趨勢與預測
  • 價值鏈分析
    • 原料
    • 服務
  • 生態系分析
  • 價格分析
    • 主要公司平均售價趨勢（2023-2025 年）
    • 按類型分類的平均售價趨勢（2023-2025 年）
  • 重大會議和活動（2026-2027）
  • 影響客戶業務的趨勢和變化
  • 投資和資金籌措場景
  • 2025年美國關稅對脂質奈米顆粒市場的影響
    • 價格影響分析
    • 對國家和地區的影響
    • 對終端用戶產業的影響

第6章：技術進步、人工智慧的影響、專利、創新與未來應用

  • 技術分析
    • 主要新興技術
    • 互補技術
    • 鄰近技術
  • 技術和產品藍圖
  • 專利分析
    • 2015-2025年脂質奈米顆粒專利的主要申請人/權利持有人（公司）
  • 未來應用
  • 人工智慧對脂質奈米顆粒市場的影響
    • 脂質奈米顆粒工作流程的最佳實踐
    • 人工智慧實施案例研究
    • 相互關聯的鄰近生態系及其對市場參與者的影響
    • 客戶對實施生成式人工智慧的準備情況

第7章：監理情勢與永續發展舉措

  • 區域法規和合規性
    • 監管情景
    • 監管機構、政府機構和其他組織
    • 業界標準
  • 永續發展計劃
  • 監理政策對永續發展措施的影響
  • 認證、標籤和環境標準

第8章：顧客趨勢與購買行為

  • 決策流程
  • 買方相關人員和採購評估標準
    • 採購過程中的關鍵相關人員
    • 終端用戶對脂質奈米顆粒原料的關鍵採購標準。
    • 最終用戶對脂質奈米顆粒服務的關鍵採購標準。
  • 實施障礙和內部挑戰
  • 各個終端用戶產業尚未滿足的需求
  • 市場盈利

第9章 LNP 原料市場：依產品分類

  • 可電離脂質
  • 聚乙二醇化脂質
  • 中性脂質
  • 磷脂
  • 試劑盒和試劑
  • 其他藥物原料

第10章：LNP原料市場：依LNP類型分類

  • 固體脂質奈米顆粒（SLNS）
  • 奈米結構脂質載體（NLCs）
  • 其他LNP類型

第11章 LNP 原料市場：依分子類型分類

  • siRNA
  • mRNA
  • 其他分子

第12章 LNP 原物料市場：依應用領域分類

  • 商業用途
  • 臨床應用

第13章：LNP原料市場：依最終用戶分類

  • 製藥和生物技術公司
  • 學術和研究機構
  • 合約研發生產組織（CDMO）

第14章 LNP 服務市場：依服務類型分類

  • 配方開發服務
  • 製造服務
  • 其他服務

第15章 LNP 服務市場：依最終用戶分類

  • 製藥和生物技術公司
  • 學術和研究機構

第16章：脂質奈米顆粒市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 亞太其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中東
    • 海灣合作理事會國家
    • 其他中東國家
  • 非洲
    • 改善醫療基礎設施將促進市場成長。

第17章 競爭格局

  • 主要參與企業的策略/優勢
  • 2019-2025年收入分析
  • 市佔率分析
    • LNP原料市場
    • LNP 服務市場
  • 企業估值矩陣：主要公司，2025 年
    • 明星公司
    • 新興領導者
    • 玩家種類繁多
    • 參與企業
    • 企業企業發展：主要公司，2025 年
  • 公司估值矩陣：新創企業/中小企業，2025 年
    • 先進公司
    • 應對力的公司
    • 充滿活力的公司
    • 起始點
    • 競爭標竿分析：新創企業/中小企業，2025 年
  • 企業估值和財務指標
    • 財務指標
    • 公司評估
  • 品牌與產品比較分析
  • 競爭格局
    • 產品及服務推出及核准
    • 交易
    • 業務拓展

第18章：公司簡介

  • 大公司
    • AVANTI POLAR LIPIDS（CRODA INTERNATIONAL PLC）
    • MERCK KGAA
    • EVONIK INDUSTRIES AG
    • NIPPON FINE CHEMICAL
    • NOF CORPORATION
    • FUJIFILM PHARMACEUTICALS USA, INC.（FUJIFILM HOLDINGS CORPORATION）
    • PRECISION NANOSYSTEMS（CYTIVA）
    • EQT AB
    • EMERGENT
    • EUROAPI
    • CAYMAN CHEMICAL
    • CORDENPHARMA
    • GATTEFOSSE
    • ACUITAS THERAPEUTICS
    • IOI OLEO GMBH
  • 其他主要公司
    • CREATIVE BIOLABS
    • CURAPATH
    • LIPOID GMBH
    • NANOCS INC.
    • MEDKOO BIOSCIENCES, INC.
    • POLYSCIENCES INC.
    • BIOVECTRA
    • ASCENDIA PHARMACEUTICALS
    • CURIA GLOBAL, INC.
    • VERNAL BIOSCIENCES

第19章：調查方法

第20章附錄

Product Code: BT 9141

The global LNP raw materials market is estimated to reach USD 395.0 million by 2031, up from USD 298.8 million in 2026, reflecting a 5.7% CAGR from 2026 to 2031. The global LNP services market is projected to reach USD 309.2 million by 2031, up from USD 161.0 million in 2026, at a 13.9% CAGR over the same period.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD million)
SegmentsProduct, Type of LNP Product, Molecule, Application, Raw Material End User, Service, Service End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

Market growth is driven by the expanding development and commercialization of mRNA vaccines and therapeutics, siRNA medicines, gene-editing therapies, and other nucleic acid-based products that require efficient intracellular delivery. Continued innovation in ionizable lipids, PEGylated lipids, phospholipids, formulation technologies, and scalable LNP manufacturing is further supporting adoption. However, the high cost and stringent quality requirements of pharmaceutical-grade lipids, formulation stability constraints, scale-up and batch-reproducibility challenges, and complex regulatory and CMC requirements are expected to restrain broader market growth.

Lipid Nanoparticles Market - IMG1

"The ionizable lipids segment accounted for the largest share of the lipid nanoparticle market, by product, in 2025."

By product, the LNP raw materials market is segmented into ionizable lipids, PEGylated lipids, neutral lipids, phospholipids, kits & reagents, and other formulation materials. In 2025, ionizable lipids accounted for the largest share of the LNP raw materials market, driven by their central role in nucleic acid encapsulation, endosomal escape, intracellular delivery efficiency, and overall LNP performance. Ionizable lipids are widely used in mRNA, siRNA, and other RNA-based formulations because they remain largely neutral at physiological pH while becoming protonated in acidic environments, thereby facilitating cargo release into the cytosol. Ongoing development of proprietary ionizable lipid chemistries, biodegradable lipid structures, and tissue-selective delivery systems continues to support strong demand from pharmaceutical & biotechnology companies and CDMOs.

"The mRNA segment is estimated to be the fastest-growing segment of the LNP market, by molecule type, from 2026 to 2031."

By molecule type, the global LNP market is segmented into siRNA, mRNA, and other molecules. During the forecast period, the mRNA segment is projected to have the highest CAGR, driven by an expanding pipeline of prophylactic and therapeutic vaccines, oncology programs, protein-replacement therapies, and other mRNA-based medicines. LNPs protect mRNA from enzymatic degradation, enhance cellular uptake, and enable efficient intracellular release, making them a key delivery platform for mRNA therapeutics. The clinical and commercial validation of LNP-enabled mRNA products, together with increased investment in next-generation mRNA platforms and broader therapeutic applications beyond infectious diseases, is expected to accelerate demand for specialized LNP raw materials, formulation development, and manufacturing services.

"Asia Pacific is projected to grow at the highest CAGR in the lipid nanoparticle market from 2026 to 2031."

The LNP market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. During the forecast period, Asia Pacific is expected to post the highest CAGR, supported by expanding biopharmaceutical and vaccine manufacturing capabilities, increased investment in RNA therapeutics and advanced drug-delivery technologies, and the growth of regional CDMOs. Countries such as China, Japan, South Korea, and India are strengthening capabilities in lipid synthesis, formulation development, nucleic acid therapeutics, and commercial-scale manufacturing. Increasing government support for biotechnology, rising R&D activity, and the expanding presence of global and regional pharmaceutical manufacturers are also expected to drive adoption of lipid nanoparticles across the region.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side - 70% and Demand Side - 30%
  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: CXOs and Directors - 30%, Managers - 45%, and Others - 25%
  • By Region: North America - 40%, Europe - 25%, Asia Pacific - 20%, Latin America - 10%, and the Middle East - 5%

List of Companies Profiled in the Report

  • Avanti Polar Lipids (Croda International plc)
  • Merck KGaA
  • Evonik Industries AG
  • Nippon Fine Chemical Co., Ltd.
  • NOF Corporation
  • FUJIFILM Pharmaceuticals, Inc. (FUJIFILM Holdings Corporation)
  • Precision NanoSystems
  • Recipharm AB
  • Emergent BioSolutions, Inc.
  • EUROAPI
  • Cayman Chemical
  • CordenPharma GmbH
  • Gattefosse
  • Acuitas Therapeutics
  • IOI Oleo GmbH

Research Coverage

The report covers detailed information on the major factors, including drivers, challenges, opportunities, and restraints, that influence the growth of the LNP market. A detailed analysis of key industry players has been conducted to provide insights into their business overviews, LNP-related raw material and service portfolios, and key strategies such as product launches, collaborations, partnerships, expansions, agreements, acquisitions, licensing activities, and recent developments associated with the market. The report also provides a competitive assessment of leading raw material suppliers, formulation technology companies, CDMOs, and other participants operating across the LNP ecosystem.

Key Benefits of Buying the Report

The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall lipid nanoparticle market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses more effectively and develop suitable market-entry and growth strategies. The report will enable stakeholders to understand the market's pulse and provide information on key market drivers, restraints, opportunities, and challenges across LNP raw materials, formulation development, and manufacturing services.

The report provides insights into the following pointers:

  • Analysis of key drivers (expanding mRNA and RNA therapeutics pipelines, increasing adoption of LNP-based nucleic acid delivery, and continuous innovation in ionizable lipid chemistry and formulation technologies), restraints (high cost and stringent quality requirements of pharmaceutical-grade lipids and formulation components), opportunities (development of biodegradable and tissue-selective ionizable lipids, extrahepatic delivery, and broader use of LNPs in gene editing and next-generation RNA therapeutics), and challenges (scale-up, batch reproducibility, formulation stability, and complex CMC and regulatory requirements) influencing the growth of the lipid nanoparticle market
  • Product Development/Innovation: Detailed insights on newly developed LNP raw materials, ionizable lipids, formulation technologies, and service capabilities
  • Market Development: Comprehensive information about lucrative markets - the report analyzes the lipid nanoparticle across varied regions
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, collaborations, licensing activities, and investments in the LNP market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product/service offerings of leading players such as Avanti Polar Lipids (Croda International plc) (US), Merck KGaA (Germany), Evonik Industries AG (Germany), Nippon Fine Chemical Co., Ltd. (Japan), NOF Corporation (Japan), among others

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 REGIONS CONSIDERED
    • 1.3.3 INCLUSIONS & EXCLUSIONS
    • 1.3.4 YEARS CONSIDERED
    • 1.3.5 CURRENCY CONSIDERED
  • 1.4 MARKET STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS IN LNP RAW MATERIALS & SERVICES MARKET
  • 2.4 HIGH GROWTH SEGMENTS
  • 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 LNP RAW MATERIALS & SERVICES MARKET OVERVIEW
  • 3.2 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT TYPE AND COUNTRY
  • 3.3 LNP RAW MATERIALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 3.4 LNP RAW MATERIALS MARKET SHARE, BY END USER, 2026 VS 2031 (%)
  • 3.5 LNP SERVICES MARKET SHARE, BY END USER, 2026 VS 2031 (%)

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Increasing use of lipid nanoparticles in anti-cancer therapies
      • 4.2.1.2 High uptake in RNA-based therapeutic research
      • 4.2.1.3 Growing government focus on R&D for LNP-based drugs
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 Stringent regulatory requirements
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Growing demand for advanced drug delivery systems
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Challenges associated with LNP formulation
  • 4.3 UNMET NEEDS & WHITE SPACES
  • 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.1.2 BARGAINING POWER OF SUPPLIERS
    • 5.1.3 BARGAINING POWER OF BUYERS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 THREAT OF NEW ENTRANTS
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS & FORECAST
    • 5.2.3 GDP TRENDS & FORECAST
  • 5.3 VALUE CHAIN ANALYSIS
    • 5.3.1 RAW MATERIALS
    • 5.3.2 SERVICES
  • 5.4 ECOSYSTEM ANALYSIS
  • 5.5 PRICING ANALYSIS
    • 5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023-2025
    • 5.5.2 AVERAGE SELLING PRICE TREND, BY TYPE (2023-2025)
  • 5.6 KEY CONFERENCES & EVENTS, 2026-2027
  • 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.8 INVESTMENT & FUNDING SCENARIO
  • 5.9 IMPACT OF 2025 US TARIFFS-LIPID NANOPARTICLES MARKET
    • 5.9.1 INTRODUCTION
    • 5.9.2 PRICE IMPACT ANALYSIS
    • 5.9.3 IMPACT ON COUNTRIES/REGIONS
      • 5.9.3.1 US
      • 5.9.3.2 Europe
      • 5.9.3.3 Asia Pacific
    • 5.9.4 IMPACT ON END-USER INDUSTRIES
      • 5.9.4.1 Pharmaceutical & biotechnology companies
      • 5.9.4.2 CROs & CDMOs
      • 5.9.4.3 Academic & research institutes

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 TECHNOLOGY ANALYSIS
    • 6.1.1 KEY EMERGING TECHNOLOGIES
      • 6.1.1.1 Nanotechnology-based drug delivery
      • 6.1.1.2 Nucleic acid delivery
    • 6.1.2 COMPLEMENTARY TECHNOLOGIES
      • 6.1.2.1 Drug encapsulation techniques
      • 6.1.2.2 Surface modification and functionalization technologies
    • 6.1.3 ADJACENT TECHNOLOGIES
      • 6.1.3.1 Biotechnology & genetic engineering technologies
      • 6.1.3.2 Nanotechnology-based formulation techniques
  • 6.2 TECHNOLOGY/PRODUCT ROADMAP
  • 6.3 PATENT ANALYSIS
    • 6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR LIPID NANOPARTICLE PATENTS, 2015-2025
  • 6.4 FUTURE APPLICATIONS
  • 6.5 IMPACT OF GENERATIVE AI ON LIPID NANOPARTICLES MARKET
    • 6.5.1 BEST PRACTICES IN LIPID NANOPARTICLE WORKFLOWS
    • 6.5.2 CASE STUDIES OF AI IMPLEMENTATION
    • 6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
    • 6.5.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

  • 7.1 REGIONAL REGULATIONS & COMPLIANCE
    • 7.1.1 REGULATORY SCENARIO
    • 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.3 INDUSTRY STANDARDS
  • 7.2 SUSTAINABILITY INITIATIVES
  • 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
  • 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 KEY BUYING CRITERIA FOR LIPID NANOPARTICLE RAW MATERIALS, BY END USER
    • 8.2.3 KEY BUYING CRITERIA FOR LIPID NANOPARTICLE SERVICES, BY END USER
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
  • 8.5 MARKET PROFITABILITY

9 LNP RAW MATERIALS MARKET, BY PRODUCT

  • 9.1 INTRODUCTION
  • 9.2 IONIZABLE LIPIDS
    • 9.2.1 HIGH DEMAND FOR MRNA-BASED VACCINES TO PROPEL MARKET
  • 9.3 PEGYLATED LIPIDS
    • 9.3.1 GROWING FOCUS ON NUCLEIC ACID MEDICINES TO BOOST DEMAND
  • 9.4 NEUTRAL LIPIDS
    • 9.4.1 ENHANCED STABILITY AND HIGH UPTAKE IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET
  • 9.5 PHOSPHOLIPIDS
    • 9.5.1 BIOLOGICAL COMPATIBILITY AND CUSTOMIZATION FEATURES TO SUPPORT MARKET GROWTH
  • 9.6 KITS & REAGENTS
    • 9.6.1 ADVANCEMENTS IN LNP FORMULATION TECHNIQUES TO DRIVE MARKET
  • 9.7 OTHER FORMULATION MATERIALS

10 LNP RAW MATERIALS MARKET, BY LNP TYPE

  • 10.1 INTRODUCTION
  • 10.2 SOLID LIPID NANOPARTICLES (SLNS)
    • 10.2.1 ADVANTAGES OVER CONVENTIONAL DRUG CARRIERS TO DRIVE MARKET
  • 10.3 NANOSTRUCTURED LIPID CARRIERS (NLCS)
    • 10.3.1 HIGH DRUG LOADING CAPACITY TO PROPEL MARKET
  • 10.4 OTHER LNP TYPES

11 LNP RAW MATERIALS MARKET, BY MOLECULE TYPE

  • 11.1 INTRODUCTION
  • 11.2 SIRNA
    • 11.2.1 GROWING FOCUS ON TARGETED DRUG DELIVERY TO DRIVE MARKET
  • 11.3 MRNA
    • 11.3.1 GROWING UPTAKE IN VACCINE DEVELOPMENT TO PROPEL MARKET
  • 11.4 OTHER MOLECULES

12 LNP RAW MATERIALS MARKET, BY APPLICATION

  • 12.1 INTRODUCTION
  • 12.2 COMMERCIAL APPLICATIONS
    • 12.2.1 POLYNEUROPATHY
      • 12.2.1.1 Ability to provide targeted & sustained release of therapeutic agents to boost demand
    • 12.2.2 OTHER COMMERCIAL APPLICATIONS
  • 12.3 CLINICAL APPLICATIONS
    • 12.3.1 COVID-19
      • 12.3.1.1 Threat of evolving emerging variants to fuel uptake
    • 12.3.2 CANCER
      • 12.3.2.1 Increasing focus on oncology therapeutics to drive market
    • 12.3.3 OTHER CLINICAL APPLICATIONS

13 LNP RAW MATERIALS MARKET, BY END USER

  • 13.1 INTRODUCTION
  • 13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 13.2.1 INCREASING DRUG DEVELOPMENT ACTIVITIES TO FUEL MARKET
  • 13.3 ACADEMIC & RESEARCH INSTITUTES
    • 13.3.1 HIGH FOCUS ON R&D FOR GENE THERAPY AND MEDICATION ADMINISTRATION TO DRIVE MARKET
  • 13.4 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS)
    • 13.4.1 GROWING OUTSOURCING OF LNP FORMULATION SERVICES TO PROPEL MARKET

14 LNP SERVICES MARKET, BY SERVICE TYPE

  • 14.1 INTRODUCTION
  • 14.2 FORMULATION DEVELOPMENT SERVICES
    • 14.2.1 GROWING FOCUS ON TARGETED & EFFECTIVE DRUG DELIVERY TO PROPEL MARKET
  • 14.3 MANUFACTURING SERVICES
    • 14.3.1 RISING DEMAND FOR LIPID-BASED CARRIERS FOR GENE THERAPY AND VACCINE DEVELOPMENT TO DRIVE MARKET
  • 14.4 OTHER SERVICES

15 LNP SERVICES MARKET, BY END USER

  • 15.1 INTRODUCTION
  • 15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 15.2.1 DRUG DEVELOPMENT & COMMERCIALIZATION TO PROPEL MARKET
  • 15.3 ACADEMIC & RESEARCH INSTITUTES
    • 15.3.1 ACCESS TO ADVANCED INFRASTRUCTURE AND SPECIALIZED EXPERTISE TO SUPPORT MARKET GROWTH

16 LIPID NANOPARTICLES MARKET, BY REGION

  • 16.1 INTRODUCTION
  • 16.2 NORTH AMERICA
    • 16.2.1 US
      • 16.2.1.1 High pharmaceutical R&D expenditure to drive market
    • 16.2.2 CANADA
      • 16.2.2.1 Growing focus on personalized medicine to drive market
  • 16.3 EUROPE
    • 16.3.1 GERMANY
      • 16.3.1.1 Rising development activities for LNP production to drive market
    • 16.3.2 UK
      • 16.3.2.1 Pioneering research programs for drug delivery systems to boost demand
    • 16.3.3 FRANCE
      • 16.3.3.1 Government funding for proteomics and genomics research to support market growth
    • 16.3.4 ITALY
      • 16.3.4.1 Growth in life sciences research to propel market
    • 16.3.5 SPAIN
      • 16.3.5.1 Growing demand for cancer therapeutics to drive market
    • 16.3.6 REST OF EUROPE
  • 16.4 ASIA PACIFIC
    • 16.4.1 CHINA
      • 16.4.1.1 Low manufacturing costs and rising outsourcing of services to CDMOs to drive market
    • 16.4.2 JAPAN
      • 16.4.2.1 Demand for LNP-based mRNA vaccines to fuel market
    • 16.4.3 INDIA
      • 16.4.3.1 Growth in pharmaceutical industry to drive market
    • 16.4.4 SOUTH KOREA
      • 16.4.4.1 Rising number of clinical trials to boost demand
    • 16.4.5 AUSTRALIA
      • 16.4.5.1 Growing requirement for innovative drug delivery systems to propel market
    • 16.4.6 REST OF ASIA PACIFIC
  • 16.5 LATIN AMERICA
    • 16.5.1 BRAZIL
      • 16.5.1.1 Global manufacturing hub for pharmaceutical drugs to fuel uptake
    • 16.5.2 MEXICO
      • 16.5.2.1 Large target patient population and demand for novel drug delivery technology to drive market
    • 16.5.3 REST OF LATIN AMERICA
  • 16.6 MIDDLE EAST
    • 16.6.1 GCC COUNTRIES
      • 16.6.1.1 Economic & healthcare expansion to support market growth
    • 16.6.2 REST OF MIDDLE EAST
  • 16.7 AFRICA
    • 16.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH

17 COMPETITIVE LANDSCAPE

  • 17.1 INTRODUCTION
  • 17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 17.3 REVENUE ANALYSIS 2019-2025
  • 17.4 MARKET SHARE ANALYSIS
    • 17.4.1 LNP RAW MATERIALS MARKET
    • 17.4.2 LNP SERVICES MARKET
  • 17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 17.5.1 STARS
    • 17.5.2 EMERGING LEADERS
    • 17.5.3 PERVASIVE PLAYERS
    • 17.5.4 PARTICIPANTS
    • 17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 17.5.5.1 Company footprint
      • 17.5.5.2 Region footprint
      • 17.5.5.3 Product footprint
      • 17.5.5.4 Application footprint
      • 17.5.5.5 Service footprint
  • 17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 17.6.1 PROGRESSIVE COMPANIES
    • 17.6.2 RESPONSIVE COMPANIES
    • 17.6.3 DYNAMIC COMPANIES
    • 17.6.4 STARTING BLOCKS
    • 17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
  • 17.7 COMPANY VALUATION & FINANCIAL METRICS
    • 17.7.1 FINANCIAL METRICS
    • 17.7.2 COMPANY VALUATION
  • 17.8 BRAND/PRODUCT COMPARISON ANALYSIS
  • 17.9 COMPETITIVE SCENARIO
    • 17.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
    • 17.9.2 DEALS
    • 17.9.3 EXPANSIONS

18 COMPANY PROFILES

  • 18.1 KEY PLAYERS
    • 18.1.1 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC)
      • 18.1.1.1 Business overview
      • 18.1.1.2 Products/Services offered
      • 18.1.1.3 Recent developments
        • 18.1.1.3.1 Product launches
        • 18.1.1.3.2 Deals
        • 18.1.1.3.3 Expansions
        • 18.1.1.3.4 Other developments
      • 18.1.1.4 MnM view
        • 18.1.1.4.1 Key strengths
        • 18.1.1.4.2 Strategic choices
        • 18.1.1.4.3 Weaknesses & competitive threats
    • 18.1.2 MERCK KGAA
      • 18.1.2.1 Business overview
      • 18.1.2.2 Products/Services offered
      • 18.1.2.3 Recent developments
        • 18.1.2.3.1 Service launches
        • 18.1.2.3.2 Expansions
      • 18.1.2.4 MnM view
        • 18.1.2.4.1 Key strengths
        • 18.1.2.4.2 Strategic choices
        • 18.1.2.4.3 Weaknesses & competitive threats
    • 18.1.3 EVONIK INDUSTRIES AG
      • 18.1.3.1 Business overview
      • 18.1.3.2 Products/Services offered
      • 18.1.3.3 Recent developments
        • 18.1.3.3.1 Deals
        • 18.1.3.3.2 Expansions
      • 18.1.3.4 MnM view
        • 18.1.3.4.1 Key strengths
        • 18.1.3.4.2 Strategic choices
        • 18.1.3.4.3 Weaknesses & competitive threats
    • 18.1.4 NIPPON FINE CHEMICAL
      • 18.1.4.1 Business overview
      • 18.1.4.2 Products/Services offered
      • 18.1.4.3 MnM view
        • 18.1.4.3.1 Key strengths
        • 18.1.4.3.2 Strategic choices
        • 18.1.4.3.3 Weaknesses & competitive threats
    • 18.1.5 NOF CORPORATION
      • 18.1.5.1 Business overview
      • 18.1.5.2 Products/Services offered
      • 18.1.5.3 Recent developments
        • 18.1.5.3.1 Deals
        • 18.1.5.3.2 Expansions
      • 18.1.5.4 MnM view
        • 18.1.5.4.1 Key strengths
        • 18.1.5.4.2 Strategic choices
        • 18.1.5.4.3 Weaknesses & competitive threats
    • 18.1.6 FUJIFILM PHARMACEUTICALS U.S.A., INC. (FUJIFILM HOLDINGS CORPORATION)
      • 18.1.6.1 Business overview
      • 18.1.6.2 Products/Services offered
      • 18.1.6.3 Recent developments
        • 18.1.6.3.1 Deals
        • 18.1.6.3.2 Expansions
    • 18.1.7 PRECISION NANOSYSTEMS (CYTIVA)
      • 18.1.7.1 Business overview
      • 18.1.7.2 Products/Services offered
      • 18.1.7.3 Recent developments
        • 18.1.7.3.1 Service launches
    • 18.1.8 EQT AB
      • 18.1.8.1 Business overview
      • 18.1.8.2 Products/Services offered
      • 18.1.8.3 Recent developments
        • 18.1.8.3.1 Deals
        • 18.1.8.3.2 Expansions
    • 18.1.9 EMERGENT
      • 18.1.9.1 Business overview
      • 18.1.9.2 Products/Services offered
    • 18.1.10 EUROAPI
      • 18.1.10.1 Business overview
      • 18.1.10.2 Products/Services offered
    • 18.1.11 CAYMAN CHEMICAL
      • 18.1.11.1 Business overview
      • 18.1.11.2 Products/Services offered
      • 18.1.11.3 Recent developments
        • 18.1.11.3.1 Product launches
        • 18.1.11.3.2 Deals
    • 18.1.12 CORDENPHARMA
      • 18.1.12.1 Business overview
      • 18.1.12.2 Products/Services offered
      • 18.1.12.3 Recent developments
        • 18.1.12.3.1 Product launches
        • 18.1.12.3.2 Deals
        • 18.1.12.3.3 Expansions
    • 18.1.13 GATTEFOSSE
      • 18.1.13.1 Business overview
      • 18.1.13.2 Products/Services offered
    • 18.1.14 ACUITAS THERAPEUTICS
      • 18.1.14.1 Business overview
      • 18.1.14.2 Products/Services offered
      • 18.1.14.3 Recent developments
        • 18.1.14.3.1 Deals
    • 18.1.15 IOI OLEO GMBH
      • 18.1.15.1 Business overview
      • 18.1.15.2 Products/Services offered
  • 18.2 OTHER PLAYERS
    • 18.2.1 CREATIVE BIOLABS
    • 18.2.2 CURAPATH
    • 18.2.3 LIPOID GMBH
    • 18.2.4 NANOCS INC.
    • 18.2.5 MEDKOO BIOSCIENCES, INC.
    • 18.2.6 POLYSCIENCES INC.
    • 18.2.7 BIOVECTRA
    • 18.2.8 ASCENDIA PHARMACEUTICALS
    • 18.2.9 CURIA GLOBAL, INC.
    • 18.2.10 VERNAL BIOSCIENCES

19 RESEARCH METHODOLOGY

  • 19.1 RESEARCH DATA
    • 19.1.1 SECONDARY DATA
    • 19.1.2 PRIMARY DATA
  • 19.2 MARKET ESTIMATION METHODOLOGY
    • 19.2.1 GLOBAL MARKET ESTIMATION
    • 19.2.2 INSIGHTS OF PRIMARY EXPERTS
  • 19.3 MARKET GROWTH RATE PROJECTIONS
  • 19.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 19.5 RESEARCH ASSUMPTIONS
  • 19.6 RESEARCH LIMITATIONS
  • 19.7 RISK ANALYSIS

20 APPENDIX

  • 20.1 DISCUSSION GUIDE
  • 20.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 20.3 CUSTOMIZATION OPTIONS
  • 20.4 RELATED REPORTS
  • 20.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 LIPID NANOPARTICLES MARKET: IMPACT ANALYSIS
  • TABLE 2 IMPACT OF PORTER'S FIVE FORCES ON THE LIPID NANOPARTICLES MARKET
  • TABLE 3 LIPID NANOPARTICLES MARKET: ROLE IN ECOSYSTEM
  • TABLE 4 AVERAGE SELLING PRICE TREND OF LNP PRODUCTS, BY KEY PLAYER, 2023-2025 (USD)
  • TABLE 5 AVERAGE SELLING PRICE TREND OF LNP PRODUCTS, BY TYPE, 2023-2025 (USD)
  • TABLE 6 LIPID NANOPARTICLES MARKET: KEY CONFERENCES & EVENTS (2026-2027)
  • TABLE 7 LIPID NANOPARTICLE MARKET: INDICATIVE LIST OF PATENTS
  • TABLE 8 CASE STUDIES OF AI IMPLEMENTATION IN LIPID NANOPARTICLES MARKET
  • TABLE 9 CLIENTS' TOP READINESS TO ADOPT GENERATIVE AI IN LIPID NANOPARTICLES MARKET
  • TABLE 10 REGULATORY SCENARIO
  • TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
  • TABLE 17 KEY BUYING CRITERIA FOR LNP RAW MATERIALS, BY END USER
  • TABLE 18 KEY BUYING CRITERIA FOR LIPID NANOPARTICLE SERVICES, BY END USER
  • TABLE 19 LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 20 IONIZABLE LIPIDS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 21 NORTH AMERICA: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 22 EUROPE: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 23 ASIA PACIFIC: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 24 LATIN AMERICA: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 25 MIDDLE EAST: IONIZABLE LIPIDS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 26 PEGYLATED LIPIDS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 27 NEUTRAL LIPIDS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 28 NORTH AMERICA: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 29 EUROPE: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 30 ASIA PACIFIC: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 31 LATIN AMERICA: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 32 MIDDLE EAST: NEUTRAL LIPIDS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 33 PHOSPHOLIPIDS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 34 NORTH AMERICA: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 35 EUROPE: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 37 LATIN AMERICA: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 38 MIDDLE EAST: PHOSPHOLIPIDS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 39 KITS & REAGENTS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 40 OTHER FORMULATION MATERIALS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 41 LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 42 SOLID LIPID NANOPARTICLES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 43 NORTH AMERICA: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 44 EUROPE: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 45 ASIA PACIFIC: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 46 LATIN AMERICA: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 47 MIDDLE EAST: SOLID LIPID NANOPARTICLES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 48 NANOSTRUCTURED LIPID CARRIERS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 49 NORTH AMERICA: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 50 EUROPE: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 52 LATIN AMERICA: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 53 MIDDLE EAST: NANOSTRUCTURED LIPID CARRIERS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 54 OTHER LNP TYPES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 55 NORTH AMERICA: OTHER LNP TYPES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 56 EUROPE: OTHER LNP TYPES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 57 ASIA PACIFIC: OTHER LNP TYPES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 58 LATIN AMERICA: OTHER LNP TYPES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 59 MIDDLE EAST: OTHER LNP TYPES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 60 LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 61 LNP RAW MATERIALS MARKET FOR SIRNA, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 62 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 63 EUROPE: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 64 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 65 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 66 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR SIRNA, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 67 LNP RAW MATERIALS MARKET FOR MRNA, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 68 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 69 EUROPE: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 70 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 71 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 72 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR MRNA, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 73 LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 74 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 75 EUROPE: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 76 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 77 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 78 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 79 LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 80 LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 81 LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 82 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 83 EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 84 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 85 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 86 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 87 LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 88 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 89 EUROPE: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 90 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 91 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 92 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 93 LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 94 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 95 EUROPE: LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 96 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 97 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 98 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 99 LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 100 LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 101 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 102 EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 103 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 104 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 105 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 106 LNP RAW MATERIALS MARKET FOR 'COVID-19, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 107 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 108 EUROPE: LNP RAW MATERIALS MARKET FOR COVID-19, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COVID-19, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 110 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 111 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COVID-19, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 112 LNP RAW MATERIALS MARKET FOR CANCER, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 113 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 114 EUROPE: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 116 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 117 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CANCER, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 118 LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 119 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 120 EUROPE: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 122 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 123 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR OTHER DISEASES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 124 LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 125 LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 126 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 127 EUROPE: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 128 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 129 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 130 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 131 LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 132 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 133 EUROPE: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 134 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 135 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 136 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 137 LNP RAW MATERIALS MARKET FOR CDMOS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 138 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 139 EUROPE: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 140 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 141 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 142 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CDMOS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 143 LNP SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
  • TABLE 144 FORMULATION DEVELOPMENT SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 145 MANUFACTURING SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 146 OTHER SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 147 LNP SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 148 LNP SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 149 LNP SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 150 LNP RAW MATERIALS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 151 LNP SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 152 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 153 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 154 NORTH AMERICA: LNP SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
  • TABLE 155 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 156 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 157 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 158 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 159 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 160 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 161 NORTH AMERICA: LNP SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 162 US: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 163 US: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 164 US: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 165 US: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 166 US: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 167 US: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 168 US: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 169 CANADA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 170 CANADA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 171 CANADA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 172 CANADA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 173 CANADA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 174 CANADA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 175 CANADA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 176 EUROPE: LNP RAW MATERIALS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 177 EUROPE: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 178 EUROPE: LNP SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
  • TABLE 179 EUROPE: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 180 EUROPE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 181 EUROPE: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 182 EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 183 EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 184 EUROPE: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 185 EUROPE: LNP SERVICES MARKET BY END USER, 2023-2031 (USD MILLION)
  • TABLE 186 GERMANY: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 187 GERMANY: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 188 GERMANY: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 189 GERMANY: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 190 GERMANY: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 191 GERMANY: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 192 GERMANY: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 193 UK: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 194 UK: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 195 UK: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 196 UK: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 197 UK: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 198 UK: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 199 UK: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 200 FRANCE: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 201 FRANCE: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 202 FRANCE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 203 FRANCE: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 204 FRANCE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 205 FRANCE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 206 FRANCE: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 207 ITALY: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 208 ITALY: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 209 ITALY: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 210 ITALY: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 211 ITALY: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 212 ITALY: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 213 ITALY: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 214 SPAIN: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 215 SPAIN: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 216 SPAIN: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 217 SPAIN: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 218 SPAIN: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 219 SPAIN: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 220 SPAIN: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 221 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 222 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 223 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 224 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 225 REST OF EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 226 REST OF EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 227 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 228 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 229 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 230 ASIA PACIFIC: LNP SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
  • TABLE 231 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 232 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 233 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 234 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 235 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 236 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 237 ASIA PACIFIC: LNP SERVICES MARKET BY END USER, 2023-2031 (USD MILLION)
  • TABLE 238 CHINA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 239 CHINA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 240 CHINA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 241 CHINA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 242 CHINA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 243 CHINA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 244 CHINA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 245 JAPAN: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 246 JAPAN: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 247 JAPAN: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 248 JAPAN: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 249 JAPAN: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 250 JAPAN: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 251 JAPAN: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 252 INDIA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 253 INDIA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 254 INDIA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 255 INDIA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 256 INDIA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 257 INDIA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 258 INDIA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 259 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 260 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 261 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 262 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 263 SOUTH KOREA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 264 SOUTH KOREA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 265 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 266 AUSTRALIA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 267 AUSTRALIA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 268 AUSTRALIA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 269 AUSTRALIA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 270 AUSTRALIA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 271 AUSTRALIA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 272 AUSTRALIA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 273 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 274 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 275 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 276 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 277 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 278 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 279 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 280 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 281 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 282 LATIN AMERICA: LNP SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
  • TABLE 283 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 284 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 285 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 286 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 287 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 288 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 289 LATIN AMERICA: LNP SERVICES MARKET BY END USER, 2023-2031 (USD MILLION)
  • TABLE 290 BRAZIL: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 291 BRAZIL: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 292 BRAZIL: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 293 BRAZIL: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 294 BRAZIL: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 295 BRAZIL: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 296 BRAZIL: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 297 MEXICO: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 298 MEXICO: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 299 MEXICO: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 300 MEXICO: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 301 MEXICO: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 302 MEXICO: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 303 MEXICO: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 304 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 305 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 306 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 307 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 308 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 309 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 310 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 311 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 312 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 313 MIDDLE EAST: LNP SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
  • TABLE 314 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 315 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 316 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 317 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 318 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 319 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 320 MIDDLE EAST: LNP SERVICES MARKET BY END USER, 2023-2031 (USD MILLION)
  • TABLE 321 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 322 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 323 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 324 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 325 GCC COUNTRIES: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 326 GCC COUNTRIES: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 327 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 328 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 329 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 330 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 331 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 332 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 333 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 334 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 335 AFRICA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 336 AFRICA: LNP SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
  • TABLE 337 AFRICA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
  • TABLE 338 AFRICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
  • TABLE 339 AFRICA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 340 AFRICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 341 AFRICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 342 AFRICA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 343 AFRICA: LNP SERVICES MARKET BY END USER, 2023-2031 (USD MILLION)
  • TABLE 344 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES, 2023-2026
  • TABLE 345 LNP RAW MATERIALS MARKET: DEGREE OF COMPETITION
  • TABLE 346 LNP SERVICES MARKET: TOP SERVICE PROVIDERS (2025)
  • TABLE 347 LIPID NANOPARTICLES MARKET: REGION FOOTPRINT
  • TABLE 348 LIPID NANOPARTICLES MARKET: PRODUCT FOOTPRINT
  • TABLE 349 LIPID NANOPARTICLES MARKET: APPLICATION FOOTPRINT
  • TABLE 350 LIPID NANOPARTICLES MARKET: SERVICE FOOTPRINT
  • TABLE 351 LIPID NANOPARTICLES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 352 LIPID NANOPARTICLES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 353 LIPID NANOPARTICLES MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 354 LIPID NANOPARTICLES MARKET: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 355 LIPID NANOPARTICLES MARKET: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 356 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): COMPANY OVERVIEW
  • TABLE 357 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): PRODUCTS/ SERVICES OFFERED
  • TABLE 358 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 359 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 360 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 361 AVANTI POLAR LIPIDS: OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 362 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 363 MERCK KGAA: PRODUCTS/SERVICES OFFERED
  • TABLE 364 MERCK KGAA: SERVICE LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 365 MERCK KGAA: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 366 EVONIK INDUSTRIES AG: COMPANY OVERVIEW
  • TABLE 367 EVONIK INDUSTRIES AG: PRODUCTS/SERVICES OFFERED
  • TABLE 368 EVONIK INDUSTRIES AG: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 369 EVONIK INDUSTRIES AG: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 370 NIPPON FINE CHEMICAL CO., LTD.: COMPANY OVERVIEW
  • TABLE 371 NIPPON FINE CHEMICAL CO., LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 372 NOF CORPORATION: COMPANY OVERVIEW
  • TABLE 373 NOF CORPORATION: PRODUCTS/SERVICES OFFERED
  • TABLE 374 NOF CORPORATION: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 375 NOF CORPORATION: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 376 FUJIFILM PHARMACEUTICALS U.S.A., INC.: COMPANY OVERVIEW
  • TABLE 377 FUJIFILM PHARMACEUTICALS U.S.A., INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 378 FUJIFILM PHARMACEUTICALS U.S.A., INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 379 FUJIFILM PHARMACEUTICALS U.S.A., INC.: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 380 PRECISION NANOSYSTEMS: COMPANY OVERVIEW
  • TABLE 381 PRECISION NANOSYSTEMS: PRODUCTS/SERVICES OFFERED
  • TABLE 382 PRECISION NANOSYSTEMS: SERVICE LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 383 RECIPHARM AB: COMPANY OVERVIEW
  • TABLE 384 RECIPHARM AB: PRODUCTS/SERVICES OFFERED
  • TABLE 385 RECIPHARM AB: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 386 RECIPHARM AB: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 387 EMERGENT: COMPANY OVERVIEW
  • TABLE 388 EMERGENT: PRODUCTS/SERVICES OFFERED
  • TABLE 389 EUROAPI: COMPANY OVERVIEW
  • TABLE 390 EUROAPI: PRODUCTS/SERVICES OFFERED
  • TABLE 391 CAYMAN CHEMICAL: COMPANY OVERVIEW
  • TABLE 392 CAYMAN CHEMICAL: PRODUCTS/SERVICES OFFERED
  • TABLE 393 CAYMAN CHEMICAL: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 394 CAYMAN CHEMICAL: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 395 CORDENPHARMA: COMPANY OVERVIEW
  • TABLE 396 CORDENPHARMA: PRODUCTS/SERVICES OFFERED
  • TABLE 397 CORDENPHARMA: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 398 CORDENPHARMA: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 399 CORDENPHARMA: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 400 GATTEFOSSE: COMPANY OVERVIEW
  • TABLE 401 GATTEFOSSE: PRODUCTS/SERVICES OFFERED
  • TABLE 402 ACUITAS THERAPEUTICS: COMPANY OVERVIEW
  • TABLE 403 ACUITAS THERAPEUTICS: PRODUCTS/SERVICES OFFERED
  • TABLE 404 ACUITAS THERAPEUTICS: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 405 IOI OLEO GMBH: COMPANY OVERVIEW
  • TABLE 406 IOI OLEO GMBH: PRODUCTS/SERVICES OFFERED
  • TABLE 407 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 408 RISK ANALYSIS

List of Figures

  • FIGURE 1 MARKET SCENARIO
  • FIGURE 2 GLOBAL LNP RAW MATERIALS MARKET, 2023-2031
  • FIGURE 3 GLOBAL LNP SERVICES MARKET, 2023-2031
  • FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN LNP RAW MATERIALS MARKET, 2023-2026
  • FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN LNP SERVICES MARKET, 2023-2026
  • FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF LNP RAW MATERIALS & SERVICES MARKET
  • FIGURE 7 HIGH-GROWTH SEGMENTS IN LNP RAW MATERIALS & SERVICES MARKET, 2026-2031
  • FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN LNP RAW MATERIALS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
  • FIGURE 9 ASIAC PACIFIC TO REGISTER HIGHEST CAGR IN LNP SERVICES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
  • FIGURE 10 INCREASING USE OF LIPID NANOPARTICLES IN RNA-BASED THERAPIES TO PROPEL LNP RAW MATERIALS MARKET
  • FIGURE 11 US AND IONIZABLE LIPIDS ACCOUNTED FOR LARGEST MARKET SHARES IN NORTH AMERICA IN 2025
  • FIGURE 12 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 14 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 15 LIPID NANOPARTICLES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 16 LIPID NANOPARTICLES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 17 LNP RAW MATERIALS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 18 LNP SERVICES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 19 LIPID NANOPARTICLES MARKET ECOSYSTEM
  • FIGURE 20 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN THE LIPID NANOPARTICLES MARKET
  • FIGURE 21 TOP APPLICANTS & OWNERS (COMPANIES) FOR LIPID NANOPARTICLE PATENTS, 2015-DECEMBER 2025
  • FIGURE 22 IMPACT OF AI/GEN AI ON LIPID NANOPARTICLES MARKET
  • FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
  • FIGURE 24 KEY BUYING CRITERIA FOR LIPID NANOPARTICLE RAW MATERIALS, BY END USER
  • FIGURE 25 KEY BUYING CRITERIA FOR LIPID NANOPARTICLE SERVICES, BY END USER
  • FIGURE 26 NORTH AMERICA: LNP RAW MATERIALS MARKET SNAPSHOT
  • FIGURE 27 ASIA PACIFIC: LNP RAW MATERIALS MARKET SNAPSHOT
  • FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN LNP RAW MATERIALS MARKET, 2019-2025 (USD MILLION)
  • FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LNP RAW MATERIALS MARKET (2025)
  • FIGURE 30 LIPID NANOPARTICLES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 31 LIPID NANOPARTICLES MARKET: COMPANY FOOTPRINT
  • FIGURE 32 LIPID NANOPARTICLES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 33 EV/EBITDA OF KEY VENDORS
  • FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 35 LIPID NANOPARTICLES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 36 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): COMPANY SNAPSHOT (2025)
  • FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT (2025)
  • FIGURE 38 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2025)
  • FIGURE 39 NIPPON FINE CHEMICAL CO., LTD.: COMPANY SNAPSHOT (2025)
  • FIGURE 40 NOF CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 41 FUJIFILM PHARMACEUTICALS U.S.A., INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 42 RECIPHARM AB: COMPANY SNAPSHOT (2025)
  • FIGURE 43 EMERGENT: COMPANY SNAPSHOT (2025)
  • FIGURE 44 EUROAPI: COMPANY SNAPSHOT (2025)
  • FIGURE 45 IOI OLEO GMBH: COMPANY SNAPSHOT (2025)
  • FIGURE 46 RESEARCH DESIGN
  • FIGURE 47 LNP RAW MATERIALS & SERVICES MARKET: BREAKDOWN OF PRIMARIES
  • FIGURE 48 LNP RAW MATERIALS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
  • FIGURE 49 LNP SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
  • FIGURE 50 MARKET SIZE ESTIMATION (RAW MATERIALS): APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025
  • FIGURE 51 MARKET SIZE ESTIMATION (SERVICES): APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025
  • FIGURE 52 ILLUSTRATIVE EXAMPLE OF NOF CORPORATION: REVENUE SHARE ANALYSIS (2025)
  • FIGURE 53 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 54 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 55 LNP RAW MATERIALS MARKET (SUPPLY SIDE): CAGR PROJECTIONS
  • FIGURE 56 LNP SERVICES MARKET (SUPPLY SIDE): CAGR PROJECTIONS
  • FIGURE 57 DATA TRIANGULATION METHODOLOGY